HIGHLIGHTSThe preclinical research collaboration with specialist drug screening company Next & Bio has been extendedThe collaboration ...
MedPage Today on MSN
Overcoming CDK4/6 Inhibitor Resistance in HR-Positive/HER2-Negative Breast Cancer
In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback